Attitudes to Vaccine Mandates among Late Adopters of COVID-19 Vaccines in Zimbabwe.
COVID-19 vaccine
vaccine hesitancy
vaccine mandates
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
07 Jul 2022
07 Jul 2022
Historique:
received:
03
06
2022
revised:
30
06
2022
accepted:
03
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
Despite sufficient supply, <25% of the population in sub-Saharan Africa has received at least one dose of COVID-19 vaccine. Vaccine mandates have previously been effective in increasing vaccine uptake. Attitudes to COVID-19 vaccine mandates and vaccines for children in African populations are not well understood. We surveyed late-adopters presenting for COVID-19 vaccination one year after program initiation in Zimbabwe. Logistic regression models were developed to evaluate factors associated with attitudes to mandates. In total, 1016 adults were enrolled; 690 (67.9%) approved of mandating vaccination for use of public spaces, 686 (67.5%) approved of employer mandates, and 796 (78.3%) approved of mandating COVID-19 vaccines for schools. Individuals of lower economic status were twice as likely as high-income individuals to approve of mandates. Further, 743 (73.1%) participants indicated that they were extremely/very likely to accept vaccines for children. Approval of vaccine mandates was strongly associated with perceptions of vaccine safety, effectiveness, and trust in regulatory processes that approved vaccines. Vaccine hesitancy is an important driver of low vaccine coverage in Africa and can be mitigated by vaccine mandates. Overall, participants favored vaccine mandates; however, attitudes to mandates were strongly associated with level of education and socioeconomic status.
Identifiants
pubmed: 35891254
pii: vaccines10071090
doi: 10.3390/vaccines10071090
pmc: PMC9316741
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Bill and Melinda Gates Foundation and Schmidt Foundation
ID : 00000
Références
Nat Med. 2021 Aug;27(8):1385-1394
pubmed: 34272499
Vaccines (Basel). 2022 May 15;10(5):
pubmed: 35632537
Vaccines (Basel). 2022 Mar 13;10(3):
pubmed: 35335070
Sci Rep. 2022 Apr 26;12(1):5966
pubmed: 35474313
Proc Natl Acad Sci U S A. 2022 Mar 29;119(13):e2118721119
pubmed: 35316133
PLoS One. 2021 May 10;16(5):e0248372
pubmed: 33970933
Vaccine. 2022 Feb 7;:
pubmed: 35153092
Virol J. 2016 Jun 03;13:87
pubmed: 27255185
Lancet. 2003 May 24;361(9371):1761-6
pubmed: 12781533
Vaccine. 1999 Oct 29;17 Suppl 3:S19-24
pubmed: 10559531
PLoS One. 2021 Dec 1;16(12):e0260575
pubmed: 34851998
Am J Infect Control. 2020 Oct;48(10):1133-1138
pubmed: 32238270
JAMA Netw Open. 2020 Dec 1;3(12):e2033324
pubmed: 33337490
PLoS One. 2022 Apr 21;17(4):e0266724
pubmed: 35446850
J Multidiscip Healthc. 2022 Jan 11;15:21-45
pubmed: 35046661
EBioMedicine. 2016 Oct;12:295-301
pubmed: 27658738
Front Public Health. 2022 May 11;10:897526
pubmed: 35646772
J Behav Med. 2022 Apr 29;:
pubmed: 35486335
Annu Rev Public Health. 2014;35:275-92
pubmed: 24328988
Vaccine. 2022 Jun 3;:
pubmed: 35773124